| Biomarker ID | 1849 |
| PMID | 30728149 |
| Year | 2019 |
| Biomarker | miR-30c-5p |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathway include: regulation of transcription by RNA polymerase II,; Gene expression (Transcription); cellular protein modification process; protein modification process; cellular metabolic process |
| Experiment | Prostate Cancer Vs Benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 4 cohorts were selected for analysis.Cohort 1 has 404 PCa, and 42 BPH, Cohort 2 has 99 BPH samples and 215 PCa samples, Cohort 3 has 148 BPH and 139 PCa samples, cohort 4 has 101 benign and 132 malignant samples |
| Senstivity | NA |
| Specificity | NA |
| AUC | Cohort 1: 0.81; Cohort 2: 0.69 |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |